Who are CYP2C19 Genotype Guided DAPT's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cyp2c19-genotype-guided-dapt.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

CYP2C19 Genotype Guided DAPT — Competitive Intelligence Brief

CYP2C19 Genotype Guided DAPT (CYP2C19 Genotype Guided DAPT) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Pharmacogenomic-guided antiplatelet therapy strategy. Area: Cardiovascular.

marketed Pharmacogenomic-guided antiplatelet therapy strategy CYP2C19 enzyme; P2Y12 receptor (indirect) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

CYP2C19 Genotype Guided DAPT (CYP2C19 Genotype Guided DAPT) — Zunyi Medical College. This is a pharmacogenomic-guided dual antiplatelet therapy (DAPT) strategy that uses CYP2C19 genotyping to optimize antiplatelet drug selection and dosing for improved cardiovascular outcomes.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CYP2C19 Genotype Guided DAPT TARGET	CYP2C19 Genotype Guided DAPT	Zunyi Medical College	marketed	Pharmacogenomic-guided antiplatelet therapy strategy	CYP2C19 enzyme; P2Y12 receptor (indirect)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Pharmacogenomic-guided antiplatelet therapy strategy class)

Zunyi Medical College · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CYP2C19 Genotype Guided DAPT — Competitive Intelligence Brief. https://druglandscape.com/ci/cyp2c19-genotype-guided-dapt. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab